Biogen (BIIB) Cash & Equivalents (2009 - 2026)

Biogen has reported Cash & Equivalents for 18 years, with the latest figure at $1.3 billion in Q2 2026.

• On a quarterly basis, Cash & Equivalents fell 53.42% year-over-year to $1.3 billion in Q2 2026; TTM through Jun 2026 was $1.3 billion, a 53.42% decrease from a year earlier, with the FY2025 full-year figure at $3.0 billion, up 26.67% from the prior year.
• Cash & Equivalents was $1.3 billion for Q2 2026 at Biogen, down from $3.4 billion in the prior quarter.
• The five-year high for Cash & Equivalents was $3.9 billion in Q3 2025, with the low at $1.0 billion in Q4 2023.
• Average Cash & Equivalents over 5 years is $2.5 billion, with a median of $2.6 billion recorded in 2023.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents tumbled 69.29% in 2023, then jumped 141.84% in 2025.
• Over 5 years, Cash & Equivalents stood at $3.4 billion in 2022, then sank by 69.29% to $1.0 billion in 2023, then surged by 126.21% to $2.4 billion in 2024, then rose by 26.67% to $3.0 billion in 2025, then plunged by 57.29% to $1.3 billion in 2026.
• The last three Cash & Equivalents figures came in at $1.3 billion (Q2 2026), $3.4 billion (Q1 2026), and $3.0 billion (Q4 2025), per Business Quant data.